These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 38654089)
41. Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia. Guan Y; Hou X; Tian P; Ren L; Tang Y; Song A; Zhao J; Gao L; Song G Front Endocrinol (Lausanne); 2021; 12():646185. PubMed ID: 33967959 [TBL] [Abstract][Full Text] [Related]
42. Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice. Liu YZ; Cheng X; Zhang T; Lee S; Yamauchi J; Xiao X; Gittes G; Qu S; Jiang CL; Dong HH J Biol Chem; 2016 Jul; 291(28):14695-705. PubMed ID: 27226540 [TBL] [Abstract][Full Text] [Related]
43. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. Kegulian NC; Ramms B; Horton S; Trenchevska O; Nedelkov D; Graham MJ; Lee RG; Esko JD; Yassine HN; Gordts PLSM Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2145-2156. PubMed ID: 31390883 [TBL] [Abstract][Full Text] [Related]
44. APOC3 Protein Is Not a Predisposing Factor for Fat-induced Nonalcoholic Fatty Liver Disease in Mice. Cheng X; Yamauchi J; Lee S; Zhang T; Gong Z; Muzumdar R; Qu S; Dong HH J Biol Chem; 2017 Mar; 292(9):3692-3705. PubMed ID: 28115523 [TBL] [Abstract][Full Text] [Related]
45. Apolipoprotein C3 is negatively associated with estrogen and mediates the protective effect of estrogen on hypertriglyceridemia in obese adults. Li J; Sun H; Wang Y; Liu J; Wang G Lipids Health Dis; 2023 Feb; 22(1):29. PubMed ID: 36855114 [TBL] [Abstract][Full Text] [Related]
48. Intestinally derived lipoprotein particles in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia. Curtin A; Deegan P; Owens D; Collins P; Johnson A; Tomkin GH Acta Diabetol; 1995 Dec; 32(4):244-50. PubMed ID: 8750763 [TBL] [Abstract][Full Text] [Related]
49. Recent advances in treating hypertriglyceridemia in patients at high risk of cardiovascular disease with apolipoprotein C-III inhibitors. Spagnuolo CM; Hegele RA Expert Opin Pharmacother; 2023 Jun; 24(9):1013-1020. PubMed ID: 37114828 [TBL] [Abstract][Full Text] [Related]
50. Rosa rugosa flavonoids exhibited PPARα agonist-like effects on genetic severe hypertriglyceridemia of mice. Baiyisaiti A; Wang Y; Zhang X; Chen W; Qi R J Ethnopharmacol; 2019 Aug; 240():111952. PubMed ID: 31100436 [TBL] [Abstract][Full Text] [Related]
52. Evidence for a complex relationship between apoA-V and apoC-III in patients with severe hypertriglyceridemia. Schaap FG; Nierman MC; Berbée JF; Hattori H; Talmud PJ; Vaessen SF; Rensen PC; Chamuleau RA; Kuivenhoven JA; Groen AK J Lipid Res; 2006 Oct; 47(10):2333-9. PubMed ID: 16861622 [TBL] [Abstract][Full Text] [Related]
53. A New Beginning for Triglyceride-Lowering Therapies. Pradhan AD Circulation; 2019 Jul; 140(3):167-169. PubMed ID: 30836784 [No Abstract] [Full Text] [Related]
54. APOC3 inhibition with volanesorsen reduces hepatic steatosis in patients with severe hypertriglyceridemia. Prohaska TA; Alexander VJ; Karwatowska-Prokopczuk E; Tami J; Xia S; Witztum JL; Tsimikas S J Clin Lipidol; 2023; 17(3):406-411. PubMed ID: 37164837 [TBL] [Abstract][Full Text] [Related]
55. Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism. Luo M; Su X; Yi Y; Yang Y; Peng D Lipids Health Dis; 2018 Jul; 17(1):160. PubMed ID: 30021607 [TBL] [Abstract][Full Text] [Related]